synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-28 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
György Kéri (Hungarian: [ˈɟørɟ ˈkeːri]; January 11, 1950 – July 20, 2016) was a Hungarian biochemist, professor and Doctor of Biological Sciences (D.Sc.). His major field of research was signal transduction therapy, and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.
=== CD200 === Basophil function is inhibited by CD200. Herpesvirus-6, herpesvirus-7, and herpesvirus-8 produce a CD200 homolog which also inhibits basophil function. This suggests that basophils may play a role in the immune response to these viruses. The role of basophils in the immune response to these viruses is further supported by findings that the CD200 receptor is expressed more frequently in basophils than in other circulating leukocytes.
An essential aspect of building an impressive upper body physique is maintaining the health and integrity of your shoulder joints [...] Deep within your shoulder are four small muscles that work in concert to stabilize your humerus as you lift weights, throw, or punch. Of the four, two that are on the back of the shoulder- infraspinatus and teres minor- externally rotate the joint and hold the ball (head of humerus) in the center of its socket (glenoid cavity). This joint centration helps prevent wear and tear in your shoulders. As the joint is centrated it is better positioned and aligned, its overall efficiency and the amount of muscular force that can be applied via it is also increased.
MHC tetramer molecules developed in a lab can mimic the antigen presenting complex on cells and bind to T-cells that recognize the antigen. Class I MHC molecules are made up of a polymorphic heavy α-chain associated with an invariant light chain beta-2 microglobulin (β2m). Escherichia coli are used to synthesize the light chain and a shortened version of the heavy chain that includes the biotin 15 amino acid recognition tag. These MHC chains are biotinylated with the enzyme BirA and refolded with the antigenic peptide of interest. Biotin is a small molecule that forms a strong bond with another protein called streptavidin. Fluorophore tagged streptavidin is added to the bioengineered MHC monomers, and the biotin-streptavidin interaction causes four MHC monomers to bind to the streptavidin and create a tetramer. When the tetramers are mixed with a blood sample, they will bind to T-cells expressing the appropriate antigen specific receptor. Any MHC tetramers that are not bound are washed out of the sample before it is analyzed with flow cytometry. Recent advancements within recombinant MHC molecules have democratised peptide MHC complex formulation and subsequent multimerisation. Highly active formulations of a broad range of MHC class I molecules now allows non-experts users to make their own custom peptide-MHC complexes from day-to-day in any lab without special equipment.
Sources: en.wikipedia.org
=== Post-Spark Therapeutics === In January 2021, High joined Asklepios Biopharmaceutical, or AskBio, a clinical-stage adeno-associated virus (AAV) gene therapy company and wholly owned subsidiary of Bayer AG, as the company's new President of Therapeutics and as a board member for AskBio. In 2024 she became Chief Executive Officer of the genetic medicine company RhyGaze.
It received some criticism from those who thought it sounded too similar to their first album. With no set band to perform the new material, Fripp and Sinfield brought Mel Collins and Gordon Haskell in as full-time members, with Haskell doubling as lead vocalist and bassist and Collins playing woodwinds and keyboards, while Andy McCulloch joined as the band's new drummer. Fripp and Sinfield wrote the band's third album, Lizard, with Haskell, Collins, and McCulloch having no say in the direction of the material. In addition to the core band, several session musicians contributed to the Lizard recording, including the returning Keith Tippett, who was offered to be a member of the new line-up, but due to other commitments could only work with the band as an occasional guest musician, and two members of Tippett's band, Mark Charig on cornet and Nick Evans on trombone. Oboe and cor anglais player Robin Miller also appeared, while Jon Anderson of Yes was brought in to sing a section of the album's title track, "Prince Rupert Awakes", which Fripp and Sinfield considered to be outside Haskell's natural range and style. Lizard featured stronger jazz and chamber-classical influences than previous albums. The album contains Sinfield's "phantasmagorical" lyrics, including "Happy Family" (an allegory of the break-up of the Beatles), and the title track, a suite which took up the entire second side, describing a medieval battle and its outcome. Released in December 1970, Lizard reached No. 29 in the UK and No. 113 in the US.
The European Central Bank's 'primary objective... shall be to maintain price stability. Without prejudice to that objective, it shall support the general economic policies in the Union', such as 'balanced economic growth and price stability, a highly competitive social market economy, aiming at full employment and social progress, and a high level of protection and improvement of the quality of the environment.' There are three main powers to achieve these goals. First, the ECB can require other banks to hold reserves proportionate to their type of lending. Second, it may lend money to other banks, or conduct 'credit operations'. Third it may 'operate in the financial markets by buying and selling' securities. For example, in Gauweiler v Deutscher Bundestag a German politician claimed that the ECB's purchase of Greek government debt on secondary markets violated TFEU article 123, which prohibits directly lending money to member state governments. The Court of Justice rejected that the ECB had engaged in 'economic policy' (i.e. fiscal transfers) rather than monetary policy decisions, which it was allowed to do. So far the ECB has failed to use these powers to eliminate investment in fossil fuels, despite the inflation that gas, oil and coal cause given their price volality in international markets. Beyond the central bank, the Credit Institutions Directive 2013 requires authorisation and prudence provisions in other banks in all EU member states.
Sources: en.wikipedia.org
=== 2023–present === NPS was reconstituted on 6 August 2023 after Aleksić left the People's Party. Alongside Aleksić, members of the National Assembly Slavica Radovanović, Borislav Novaković, and Đorđe Stanković, and councillors in the City Assembly of Belgrade joined the party. Aleksić announced that the party would begin collecting signatures to again become a registered political party. On 25 August, Aleksić announced that they collected over 10,000 signatures. The party was subsequently registered in October 2023. NPS became part of the Serbia Against Violence coalition in October 2023, a coalition of political parties organising the 2023 protests.
From the first partition of Poland (1772): Polish Inflants (Latgale), the northern part of the Polotsk Voivodeship, the entire Mstsislaw Voivodeship and Vitebsk Voivodeships, and the southeastern part of the Minsk Voivodeship (about 92,000 km2) From the second partition of Poland (1793): the remaining part of the Minsk Voivodeship, the entire Kiev Voivodeship, Bracław Voivodeship and Vilnius Voivodeships, parts of Podole Voivodeship and eastern parts of the Wołyń Voivodeship and Brest Litovsk Voivodeships (about 250,000 km2) From the third partition of Poland (1795): all the territories east of the Bug River(about 120,000. km2) and after 1807 the Belostok Oblast) It consisted of 9 guberniyas: six Belarusian and Lithuanian ones that constituted the Northwestern Krai (Vilna Governorate, Kovno Governorate, Grodno Governorate, Minsk Governorate, Mogilev Governorate and Vitebsk Governorate) and three Ukrainian ones that constituted the Southwestern Krai (Volhynia Governorate, Podolia Governorate and Kiev Governorate). In the first partition, Russia gained 92,000 km2 and 1.3 million people. In the second, 250,000 km2 and 1 million people. In the third, 120,000 km2 and 1.2 million people. Overall, Russia had gained about 62 percent of the former Commonwealth territory (462,000 km2) and about 45 percent of the population (3.5 million people). The Russian partition was thus the largest and most populous of the three partitions (the other two being the Austrian Partition and the Prussian Partition).
== Distribution == Hydrothermal vents are distributed along the Earth's plate boundaries, although they may also be found at intra-plate locations such as hotspot volcanoes. As of 2009 there were approximately 500 known active submarine hydrothermal vent fields, with about half visually observed at the seafloor and the other half suspected from water column indicators and/or seafloor deposits.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.